Amundi Increases Stock Position in The Clorox Company $CLX

Amundi increased its holdings in shares of The Clorox Company (NYSE:CLX) by 1.1% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 940,399 shares of the company’s stock after acquiring an additional 10,108 shares during the period. Amundi owned approximately 0.76% of Clorox worth $117,230,000 at the end of the most recent reporting period.

Several other large investors have also recently modified their holdings of CLX. American National Bank & Trust lifted its stake in shares of Clorox by 69.5% in the second quarter. American National Bank & Trust now owns 217 shares of the company’s stock worth $26,000 after buying an additional 89 shares in the last quarter. NewSquare Capital LLC lifted its holdings in Clorox by 567.6% in the second quarter. NewSquare Capital LLC now owns 227 shares of the company’s stock valued at $27,000 after acquiring an additional 193 shares during the period. Hantz Financial Services Inc. bought a new stake in Clorox during the second quarter valued at approximately $31,000. Ransom Advisory Ltd bought a new position in Clorox in the 1st quarter worth $35,000. Finally, MTM Investment Management LLC purchased a new stake in Clorox in the 2nd quarter worth approximately $37,000. Hedge funds and other institutional investors own 78.53% of the company’s stock.

Clorox Stock Performance

Shares of CLX stock opened at $104.87 on Monday. The business has a fifty day moving average of $111.94 and a 200 day moving average of $120.14. The firm has a market capitalization of $12.79 billion, a price-to-earnings ratio of 16.46, a price-to-earnings-growth ratio of 0.52 and a beta of 0.57. The Clorox Company has a 1 year low of $98.20 and a 1 year high of $171.37. The company has a debt-to-equity ratio of 18.01, a current ratio of 0.76 and a quick ratio of 0.50.

Clorox (NYSE:CLX) last posted its quarterly earnings results on Monday, November 3rd. The company reported $0.85 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.78 by $0.07. Clorox had a net margin of 11.68% and a return on equity of 358.39%. The company had revenue of $1.43 billion during the quarter, compared to analyst estimates of $1.41 billion. During the same period last year, the firm posted $1.86 EPS. Clorox’s revenue for the quarter was down 18.9% compared to the same quarter last year. Clorox has set its FY 2026 guidance at 5.950-6.300 EPS. As a group, research analysts expect that The Clorox Company will post 7.15 earnings per share for the current year.

Clorox Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, February 13th. Investors of record on Wednesday, January 28th will be paid a $1.24 dividend. This represents a $4.96 annualized dividend and a dividend yield of 4.7%. The ex-dividend date is Wednesday, January 28th. Clorox’s payout ratio is currently 77.86%.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on CLX shares. TD Cowen cut their target price on shares of Clorox from $120.00 to $117.00 and set a “hold” rating for the company in a research note on Wednesday, October 1st. Barclays reduced their target price on shares of Clorox from $112.00 to $108.00 and set an “underweight” rating on the stock in a research note on Tuesday, November 4th. Rothschild & Co Redburn cut their price objective on Clorox from $120.00 to $115.00 and set a “neutral” rating on the stock in a research report on Wednesday, November 5th. Jefferies Financial Group reiterated a “buy” rating and issued a $152.00 price target on shares of Clorox in a report on Tuesday, November 4th. Finally, Morgan Stanley reduced their price target on shares of Clorox from $137.00 to $125.00 and set an “equal weight” rating for the company in a report on Tuesday, November 4th. One equities research analyst has rated the stock with a Buy rating, thirteen have assigned a Hold rating and four have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Clorox presently has an average rating of “Reduce” and an average target price of $125.69.

Insider Buying and Selling

In other Clorox news, Director Pierre R. Breber acquired 4,000 shares of the business’s stock in a transaction dated Friday, November 21st. The stock was acquired at an average cost of $104.13 per share, for a total transaction of $416,520.00. Following the completion of the transaction, the director directly owned 13,000 shares of the company’s stock, valued at $1,353,690. This represents a 44.44% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 0.63% of the company’s stock.

About Clorox

The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers cleaning products, such as laundry additives and home care products primarily under the Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex, and Formula 409 brands; professional cleaning and disinfecting products under the CloroxPro and Clorox Healthcare brands; professional food service products under the Hidden Valley brand; and vitamins, minerals and supplement products under the RenewLife, Natural Vitality, NeoCell, and Rainbow Light brands in the United States.